1. Search Result
Search Result
Results for "

CD33

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

14

Inhibitory Antibodies

40

Recombinant Proteins

6

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144399

    Transmembrane Glycoprotein Neurological Disease
    CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease .
    CD33 splicing modulator 1
  • HY-P99329

    Anti-Human CD33 Recombinant Antibody

    Transmembrane Glycoprotein Cancer
    Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
    Vadastuximab
  • HY-109539

    Antibody-Drug Conjugates (ADCs) Apoptosis Cancer
    Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). The antibody portion is Gemtuzumab (HY-P99971), and the drug-linker conjugate for ADC is N-Ac-γ-Calicheamicin-AcBut-NHS ester (HY-103688). Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML) .
    Gemtuzumab ozogamicin
  • HY-P99958

    AMV-564; TandAb T564

    Transmembrane Glycoprotein Cancer
    Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .
    Vixtimotamab
  • HY-144399A

    Transmembrane Glycoprotein Neurological Disease
    CD33 splicing modulator 1 (Compound 1) hydrochloride is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid cell surface receptor known to regulate microglial activity. CD33 splicing modulator 1 hydrochloride increases exon 2 skipping in the cellular mRNA pool and can be used to study neurodegenerative diseases including Alzheimer's disease .
    CD33 splicing modulator 1 hydrochloride
  • HY-RS23537

    Small Interfering RNA (siRNA) Others

    Cd33 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cd33 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd33 Rat Pre-designed siRNA Set A
    Cd33 Rat Pre-designed siRNA Set A
  • HY-RS02235

    Small Interfering RNA (siRNA) Others

    CD33 Human Pre-designed siRNA Set A contains three designed siRNAs for CD33 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD33 Human Pre-designed siRNA Set A
    CD33 Human Pre-designed siRNA Set A
  • HY-RS17093

    Small Interfering RNA (siRNA) Others

    Cd33 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd33 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd33 Mouse Pre-designed siRNA Set A
    Cd33 Mouse Pre-designed siRNA Set A
  • HY-171792

    ORM-6151

    Transmembrane Glycoprotein Cancer
    BMS-986497 (ORM-6151) is a CD33-targeted antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells, inducing GSPT1 protein degradation. BMS-986497 is promising for research of acute myeloid leukemia (AML) .
    BMS-986497
  • HY-P990903

    CD3 Inflammation/Immunology
    HY-P990903 is an CD3E/CD33-targeting [H-γ1 _ L-κ-scFv heavy -κ]-dimer type bispecific antibody .
    Avitotamig
  • HY-P99971

    ADC Antibody Transmembrane Glycoprotein Cancer
    Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Gemtuzumab
  • HY-P991517

    Transmembrane Glycoprotein Cancer
    BI-836858 is a fully humanized IgG1 anti-CD33 monoclonal antibody. BI-836858 is Fc-engineered for increased binding to FcγRIIIa (CD16). BI-836858 has antibody-dependent cellular cytotoxicity (ADCC) activities. BI-836858 can be used for the study of acute myeloid leukemia (AML) .
    BI-836858
  • HY-P9983

    SGN-33; HuM-195

    Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs) Inflammation/Immunology
    Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
    Lintuzumab
  • HY-P990505

    Transmembrane Glycoprotein Inflammation/Immunology
    The Anti-Siglec-15/CD33L3 Antibody is a human-derived antibody expressed in CHO cells, targeting Siglec-15/CD33L3. The Anti-Siglec-15/CD33L3 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for the Anti-Siglec-15/CD33L3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-Siglec-15/CD33L3 Antibody
  • HY-P991365

    Transmembrane Glycoprotein Endocrinology
    DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    DS-1501
  • HY-P991364

    PYX-106; BSI-060T

    Transmembrane Glycoprotein Cancer
    Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Aldastotug
  • HY-160649

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-Gly-Gly-Phe-Gly-GABA-Exatecan is an agent linker conjugate for ADC, with an inhibitor for Topoisomerase Exatecan (HY-13631) with IC50 of 22 μM. MC-Gly-Gly-Phe-Gly-GABA-Exatecan targets various antibodies, exhibits cytotoxic and antitumor efficacy in vitro and in vivo .
    MC-Gly-Gly-Phe-Gly-GABA-Exatecan

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: